Uchikov Petar, Khalid Usman, Dedaj-Salad Granit Harris, Ghale Dibya, Rajadurai Harney, Kraeva Maria, Kraev Krasimir, Hristov Bozhidar, Doykov Mladen, Mitova Vanya, Bozhkova Maria, Markov Stoyan, Stanchev Pavel
Department of Special Surgery, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Faculty of Medicine, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria.
Life (Basel). 2024 Nov 8;14(11):1451. doi: 10.3390/life14111451.
Breast cancer is the most prevalent cancer worldwide, affecting both low- and middle-income countries, with a growing number of cases. In 2024, about 310,720 women in the U.S. are projected to receive an invasive breast cancer diagnosis, alongside 56,500 cases of ductal carcinoma in situ (DCIS). Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life. About 65% of women with the and 45% with the gene variants develop breast cancer by age 70. While these genes account for 5% of breast cancers, their prevalence is higher in certain populations. Advances in early detection, personalised medicine, and AI-driven diagnostics are improving outcomes by enabling a more precise analysis, reducing recurrence, and minimising treatment side effects. Our paper aims to explore the vast applications of artificial intelligence within the diagnosis and treatment of breast cancer and how these advancements can contribute to elevating patient care as well as discussing the potential drawbacks of such integrations into modern medicine. We structured our paper as a non-systematic review and utilised Google Scholar and PubMed databases to review literature regarding the incorporation of AI in the diagnosis and treatment of non-palpable breast masses. AI is revolutionising breast cancer management by enhancing imaging, pathology, and personalised treatment. In imaging, AI can improve the detection of cancer in mammography, MRIs, and ultrasounds, rivalling expert radiologists in accuracy. In pathology, AI enhances biomarker detection, improving and assessments. Personalised medicine benefits from AI's predictive power, aiding risk stratification and treatment response. AI also shows promise in triple-negative breast cancer management, offering better prognosis and subtype classification. However, challenges include data variability, ethical concerns, and real-world validation. Despite limitations, AI integration offers significant potential in improving breast cancer diagnosis, prognosis, and treatment outcomes.
乳腺癌是全球最常见的癌症,影响着低收入和中等收入国家,且病例数不断增加。2024年,预计美国约有310,720名女性将被诊断为浸润性乳腺癌,另有56,500例导管原位癌(DCIS)。乳腺癌在世界上每个国家的青春期后女性中都有发生,但随着年龄增长发病率会上升。携带 基因变异的女性中约65%以及携带 基因变异的女性中约45%在70岁前会患乳腺癌。虽然这些基因导致的乳腺癌占5%,但其在某些人群中的患病率更高。早期检测、个性化医疗和人工智能驱动诊断方面的进展通过实现更精确的分析、降低复发率和最小化治疗副作用,正在改善治疗效果。我们的论文旨在探讨人工智能在乳腺癌诊断和治疗中的广泛应用,以及这些进展如何有助于提升患者护理水平,并讨论将其整合到现代医学中的潜在弊端。我们将论文结构为非系统性综述,并利用谷歌学术和PubMed数据库来回顾有关人工智能在不可触及乳腺肿块诊断和治疗中的应用的文献。人工智能正在通过增强成像、病理学和个性化治疗来彻底改变乳腺癌管理。在成像方面,人工智能可以提高乳腺X线摄影、磁共振成像和超声检查中癌症的检测率,在准确性上可与专家放射科医生相媲美。在病理学方面,人工智能增强生物标志物检测,改善 和 评估。个性化医疗受益于人工智能的预测能力,有助于风险分层和治疗反应评估。人工智能在三阴性乳腺癌管理中也显示出前景,可提供更好的预后和亚型分类。然而,挑战包括数据可变性、伦理问题和现实世界验证。尽管存在局限性,但人工智能整合在改善乳腺癌诊断、预后和治疗效果方面具有巨大潜力。